Potential impacts of schedule changes, waning immunity and vaccine uptake on measles elimination in Australia

Vaccine

Volumn 27, Issue 2, 2009, Pages 313-318

  Wood, James G ^a,b   Gidding, Heather F ^c   Heywood, Anita ^a   Macartney, Kristine ^a   McIntyre, Peter B ^a,b   MacIntyre, C Raina ^a,b  

^a CHILDREN S HOSPITAL AT WESTMEAD   (Australia)

^b UNIVERSITY OF SYDNEY   (Australia)

^c Western Sydney Area Health Service   (Australia)

Author keywords

Measles; Modelling; Vaccination

Indexed keywords

MEASLES MUMPS RUBELLA VACCINE;

ARTICLE; AUSTRALIA; DRUG DOSE REGIMEN; IMMUNITY; INFECTION CONTROL; INFECTION PREVENTION; INFECTION SENSITIVITY; MEASLES VACCINATION; MODEL; PRIORITY JOURNAL; SEROCONVERSION;

AGE FACTORS; ANTIBODIES, VIRAL; AUSTRALIA; CHILD, PRESCHOOL; DISEASE SUSCEPTIBILITY; HUMANS; IMMUNITY; IMMUNIZATION SCHEDULE; INFANT; MEASLES; MEASLES VACCINE; MEASLES-MUMPS-RUBELLA VACCINE; MODELS, BIOLOGICAL;

EID: 57149088812     PISSN: 0264410X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.vaccine.2008.09.095     Document Type: Article

References (24)

1. Heywood A, Gidding HF, Riddell MA, McIntyre PB, MacIntyre CR, Kelly H. Elimination of indigenous measles transmission in Australia. Bulletin of the World Health Organisation; in press, doi:10.2471/BLT.07.046375.
2. Gidding H.F., Wood J., MacIntyre C.R., Kelly H., Lambert S.B., Gilbert G.L., et al. Sustained measles elimination in Australia and priorities for long term maintenance. Vaccine 25 (2007) 3574-3580
3. Babad H.R., Nokes D.J., Gay N.J., Miller E., Morgan-Capner P., and Anderson R.M. Predicting the impact of measles vaccination in England and Wales: model validation and analysis of policy options. Epidemiology and Infection 114 2 (1995) 319-344
4. Gay N.J., Pelletier L., and Duclos P. Modelling the incidence of measles in Canada: an assessment of the options for vaccination policy. Vaccine 16 8 (1998) 794-801
5. Hull B.P., McIntyre P.B., Heath T.C., and Sayer G.P. Measuring immunisation coverage in Australia. Australian Family Physician 28 (1999) 55-60
6. MacIntyre C.R., Gay N.J., Gidding H.F., Hull B.P., Gilbert G.L., and McIntyre P.B. A mathematical model to measure the impact of the Measles Control Campaign on the potential for measles transmission in Australia. International Journal of Infectious Diseases 6 4 (2002) 1-6
7. de Serres G., Boulianne N., Meyer F., and Ward B.J. Measles vaccine efficacy during an outbreak in a highly vaccinated population: incremental increase in protection with age at vaccination up to 18 months. Epidemiology and Infection 115 2 (1995) 315-323
8. Bin D., Zhihui C., Qichang L., Ting W., Chengyin G., Xingzi W., et al. Duration of immunity following immunization with live measles vaccine: 15 years of observation in Zhejiang Province, China. WHO Bulletin 69 (1991) 415-423
9. Krugman S. Present status of measles and rubella immunization in the United States: a medical progress report. The Journal of Pediatrics 90 1 (1977) 1-12
10. Davidkin I., Jokinen S., Broman M., Leinikki P., and Peltola H. Persistence of measles, mumps, and rubella antibodies in an MMR-Vaccinated Cohort: a 20-year follow-up. Journal of Infectious Diseases 197 (2008) 950-956
11. Davidkin I., and Valle M. Vaccine-induced measles virus antibodies after two doses of combined measles, mumps and rubella vaccine: a 12-year follow-up in two cohorts. Vaccine 16 20 (1998) 2052-2057
12. Kremer J.R., Schneider F., and Muller C.P. Waning antibodies in measles and rubella vaccinees-a longitudinal study. Vaccine 24 (2006) 2594-2601
13. LeBaron C.W., Beeler J., Sullivan B.J., Forghani B., Bi D., Beck C., et al. Persistence of measles antibodies after 2 doses of measles vaccine in a postelimination environment. Archives of Pediatric and Adolescent Medicine 161 (2007) 294-301
14. Vandermeulen C., Roelants M., Leroux-Roels G., Van Damme P., and Hoppenbrouwers K. Long-term persistence of antibodies after one or two doses of MMR-vaccine. Vaccine 25 (2007) 6672-6676
15. Glass K., and Grenfell B.T. Antibody dynamics in childhood diseases: waning and boosting of immunity and the impact of vaccination. Journal of Theoretical Biology 221 (2003) 121-131
16. Mossong J., Nokes D.J., Edmunds W.J., Cox M.J., Ratnam S., and Muller C.P. Modeling the impact of subclinical measles transmission in vaccinated populations with waning immunity. American Journal of Epidemiology 150 11 (1999) 1238-1249
17. Samb B., Aaby P., Whittle H.C., Seck A.M.C., Rahman S., Bennett J., et al. Serologic status and measles attack rates among vaccinated and unvaccinated children in rural Senegal. Pediatric Infectious Disease Journal 14 (1995) 203-209
18. Gay N.J., Hesketh L.M., Morgan-Capner P., and Miller E. Interpretation of serological surveillance data for measles using mathematical models: implications for vaccine strategy. Epidemiology and Infection 115 1 (1995) 139-156
19. June 2005 (Reissue): Australian Bureau of Statistics; 2005. Report No.: 4402.0.
20. Lawrence G.L., MacIntyre C.R., Hull B.P., and McIntyre P.B. Measles vaccination coverage among five-year-old children: implications for disease elimination in Australia. Australian and New Zealand Journal of Public Health 27 4 (2003) 413-418
21. Hull B.P., and McIntyre P.B. Mapping immunisation coverage and conscientious objectors to immunisation in NSW. NSW Public Health Bulletin 14 (2003) 8-12
22. Australian Bureau of Statistics. Child Care Australia. 2006.
23. National Health and Medical Research Council, editor. The Australian Immunisation Handbook. 9th ed. Canberra: National Capital Press. 2008.
24. Anderson R.M., and May R.M. Infectious diseases of humans: dynamics and control (1991), Oxford University Press, Oxford